Article

Intravitreal fluocinolone implant shows efficacy in diabetic macular edema but complications common

Two-year results from a multicenter, randomized, masked trial show a0.5 mg fluocinolone acetonide sustained-release, intravitreal implant issignificantly more effective in resolving retinal thickening at the centerof the macula and improving visual acuity in eyes with diabetic macularedema compared with standard of care. However, the steroid has also beenassociated with high rates of cataract progression and increased IOP, reportedAndy Pearson, MD.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.